Scinai Immunotherapeutics ( (SCNI) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Scinai Immunotherapeutics Ltd. has announced a delay in filing its Annual Report on Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to complex accounting analysis and valuation efforts related to the conversion of a $29 million European Investment Bank loan to preferred equity, compounded by unexpected personnel resource losses. The company anticipates filing the report by May 15, 2025. Despite the delay, Scinai does not expect significant changes in its financial results from the previous fiscal year. The company is actively working on compliance, with the notification signed by Chief Financial Officer Uri Ben-Or.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
YTD Price Performance: -29.07%
Average Trading Volume: 16,520
Technical Sentiment Signal: Buy
Current Market Cap: $2.08M
See more data about SCNI stock on TipRanks’ Stock Analysis page.